Free Trial
NYSE:AMPE

Ampio Pharmaceuticals (AMPE) Stock Price, News & Analysis

Ampio Pharmaceuticals logo
$0.0027 -0.08 (-96.77%)
As of 08/29/2025 12:04 PM Eastern

About Ampio Pharmaceuticals Stock (NYSE:AMPE)

Key Stats

Today's Range
$0.0027
$0.0027
50-Day Range
N/A
52-Week Range
$0.00
$0.13
Volume
168 shs
Average Volume
722 shs
Market Capitalization
$3.06 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive AMPE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ampio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AMPE Stock News Headlines

AMPE Ampio Pharmaceuticals, Inc.
Man Who Called Nvidia at $1.10 Says Buy This Now...
In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.tc pixel
Ampio Pharmaceuticals, Inc. (AMPE)
See More Headlines

AMPE Stock Analysis - Frequently Asked Questions

Ampio Pharmaceuticals' stock was trading at $0.0026 on January 1st, 2025. Since then, AMPE shares have increased by 3.8% and is now trading at $0.0027.

Ampio Pharmaceuticals, Inc. (NYSE:AMPE) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.40).

Ampio Pharmaceuticals's stock reverse split on Tuesday, September 12th 2023.The 1-20 reverse split was announced on Thursday, August 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of AMPE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ampio Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Trevena (TRVN), GE Aerospace (GE) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

Last Earnings
11/10/2021
Today
9/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:AMPE
CIK
1411906
Employees
20
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.04 per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
1,135,000
Free Float
1,098,000
Market Cap
$3.06 thousand
Optionable
No Data
Beta
5.09

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NYSE:AMPE) was last updated on 9/2/2025 by MarketBeat.com Staff
From Our Partners